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Rede 
Uitgesproken bi de aanvaarding van het ambt van bijzonder hoogleraar cardiologie in 
het bijzondere clinical heart failure aan de Faculty of Health , Medicine and Life Sciences van 
de Universiteit Maastricht 
Maastricht, 27 juni 2014 
Prof.dr. H.P. Brunner-La Rocca 
  
Mijnheer de rector magnificus 
Decaan van de Faculteit Health, Medicine and Life Sciences 
Gewaardeerde collega’s 
Lieve familie en vrienden 
Geachte toehoorders 
In principe zou ik mijn oratie graag in het Nederlands willen houden. Niet om te laten 
zien dat het toch redelijk zou lukken. Ook niet alleen om te laten zien dat ik het ook zo 
bedoel als ik zeg dat ik de mensen hier in Nederland niet alleen wil verstaan, maar ook 
begrijpen. Nee, ik zou het vooral willen omdat het Nederlands deel van mijn leven is 
geworden alsof ik dat ooit had gedacht. Maar zoals u zult horen en het ongetwijfeld ook 
weet is mijn connectie met Zwitserland en de vrienden welke er wonen nog steeds sterk en 
ik stel het erg op prijs dat zo vele hier naartoe zijn gekomen. Daarom zal ik mijn oratie in het 
Engels houden. 
It took me quite a while to now giving my inaugural lecture. To make the step working 
in another country away from home was in the end more difficult than I had thought. I had 
already once before the chance to train how it would be during our stay in Melbourne 
Australia, but making this step not just temporarily is different and quite an adventure. It is 
an experience to get settled in a new environment. You may think that there is hardly any 
difference between Switzerland and the Netherlands, both are small countries, both are 
sharing quite some common expertise and interests, both have similar things that are 
important to people. But, there is a difference. In the meantime, I have learned a lot. I have 
learned how to thoroughly discuss things. I learned that Limburg is well a province of the 
Netherlands, but that it is not Holland, even though they share some common interests. 5 
years ago, I did not know the difference; now I do know. I also learned that if you get an 
invitation at 8 pm. you are expected to be fed. And I learned that “yes” does not always 
mean “yes” and “maybe” means “no”, but also that even a clear “no” always leaves the 
option for a second chance.  
I have also learned about important differences in the health care systems of the two 
countries. Having basically no specialists in private practice, a much stronger influence of 
health care insurers, a different financial system with DRG’s/DOT’s also in outpatient care 
require a different set-up of and approach to care. Comparing systems and learning from it 
provides interesting insights in health care that can be used to improve the care we are 
delivering to our patients.  
But most importantly, I met many very friendly, helpful and enthusiastic people. I 
came along at a relatively young university; something I did not know from the past as both 
universities where I was working in Switzerland have been established for hundreds of years. 
There are some things specific to a new university, I think. There is the problem of being 
questioned, of being forced to prove the importance of the own existence. This might be 
seen as drawback, but to me, it is mainly an interesting challenge. A new university also 
means having a spirit of enthusiasm, achieving something new, reaching out for success. The 
same reasons were main drivers for me to do the step of going abroad. These attributes that 
we have here are crucial to tackle the challenges that are present for ongoing changes in 
health care, in education, but also in research. 
Collaboration in this is very important. Something that took some effort for me to be 
achieved, but we are really making progress; within our heart failure cluster, within 
Cardiology, but also with other departments and even across schools; an aspect of my work 
that is really enjoyable. It is an honour to be part of a department where big discoveries in 
Cardiology have been made, but this obviously also asks for commitment. To a significant 
extent, this is visible and I am impressed about the expertise and knowledge that is available 
here in Maastricht. This is another important motivation for me to work here. Still, we must 
keep living up to this commitment and our expectations. 
The controversy between being questioned and wanting to perform and to achieve 
more should not result to try to imitate what others are doing. In some ways, there are 
tendencies in this direction with e.g. too narrow foci on very specific topics. Instead, we 
should ask ourselves what are we really good in and what are we wanting to achieve in the 
future. Obviously, it is not my task to do this in a very broad term. Still, in Cardiology, I may 
dare to say that our strengths are not limited to one specific topic, but more the impressive 
variety of expertise present, from bench to bedside. This became also obvious during the 
external review of CARIM that had taken place this month. Even more importantly, the 
different groups are exchanging ideas and are collaborating. There are certainly fields, where 
we could, no must further improve. We also must be more visible from the outside herein. 
But, we have a good basis to be very successful in this regard. In many ways, this is the topic 
of my speech today. 
The topic of my speech is, as you know, “towards personalized medicine…”. And to me, 
this obviously means in heart failure. But how can I say that we should not be focussing on 
one specific topic if I am saying to do the same? This is obviously the challenge in this. Being 
broadly focused… a “contradictio in adiecto”, a contradiction in terms? I do not think so. To 
me, personalized medicine is asking for more than what we have been doing in Cardiology so 
far. And heart failure is the perfect playground for this; complex, being the (end-)result of 
almost all cardiac diseases, dealing with patients that usually do not only have heart failure, 
but many other diseases, numerous adaptive mechanisms being of importance, despite 
advantages in the recent decades still much to be achieved, both with respect to outcome 
and quality of life of patients, and in particular, a one-fits all approach with very little 
attempts to go in a different direction. 
Heart failure – a common and deadly disease 
Heart failure is mainly, but not exclusively a disease of the elderly. The prevalence 
increases with age from far below 1% at the age below 50 years to 10% or more in people 
aged above 75 years. Thus, at least ever 10th person at this age has heart failure. It is 
estimated that app. 15 million patients suffer from heart failure in Europe and there are 
more than one million new cases each year worldwide. Heart failure is the most common 
reason for hospitalization in patients aged more than 65 years. As a consequence, it is also a 
very costly disease, accounting for app. 2% of the total health care budget in developed 
countries. 
Usually, heart failure is a progressive disease(1). There are some exceptions such as 
some patients with myocarditis or as a result of exposure to toxic substances such as alcohol 
or chemotherapy. In the majority, however, patients do not completely recover from it. 
After initial presentation with symptoms such as shortness of breath, the patients usually 
can be stabilized with current treatment. Still, after a period of little symptoms, which may 
vary significantly from months to more than a decade in individual patients, cardiac function 
progressively deteriorates with episodes of hospital admission. Functioning of the patients 
gradually deteriorates until the terminal stage, finally leading to death. Some patients may 
also die suddenly from fatal arrhythmias at earlier stages. Treatment of heart failure is 
obviously to prevent both as far as possible. 
And, we have been quite successful in this during the last 25 years. In the late 80’s, 
more than half of the patients with advanced heart failure died within one year! 
Undoubtedly, one of the most deadly diseases then. Fortunately, different types of 
medication and also device therapy such as implantable defibrillators and biventricular 
pacemakers have dramatically improved outcome in heart failure patients. Based on the 
large studies that have investigated these therapies, one could expect a yearly mortality rate 
of 10% or even less. However in clinical reality, figures are less optimistic than this. In our 
own hospital, app. 10% of the patients that are admitted with the diagnosis of heart failure 
die during the hospital stay and app. 13% are readmitted to hospital with 30 days (Source: 
Global Comparators provided by dr. Foster, UK)! These data have been collected in an 
international collaboration with 44 institutions in 8 different countries called Global 
Comparators. This collaboration is to improve in-hospital care by comparing data and 
exchanging information on organization of care. The big need of such initiatives is 
highlighted by results such as ours that are similarly being seen in other centres. Also during 
post-discharge care, there is still much to be won as shown by the results of the TIME-CHF 
study, which included a typical heart failure population with an average age of 76 years. 
Mortality during the first year was 20% and 50% died within 4 years after discharge from 
hospital(2, 3). 
The question obviously arises why are these figures much worse than what might be 
expected from the large clinical trials? There are several answers to this, but frankly, much is 
unknown about it. What certainly plays a role is the presence of multiple diseases other than 
heart failure in the majority of patients, called co-morbidities. As recently described in the 
US patients hospitalised with heart failure, hospitalisation primarily due to heart failure tend 
to decrease from 30% in 2001 to 26% in 2009 of all hospitalisations related to heart 
failure(4). In contrast, heart failure hospitalisations accompanied with other problems have 
been increasing. Thus, renal failure was a major reason for admission in 11% in 2001, but 
increased to 40% in 2009, and mental illnesses increased from 25% to 38%. Other diseases 
increased less dramatically, but these figures illustrate the increasing complexity of patients 
with heart failure. In such patients, in-hospital mortality is more than twice the mortality of 
those with heart failure only. 
Another potential reason for the less favourable outcome is insufficient adherence of 
physicians to guidelines. In a survey, cardiologists, internists and geriatricians were asked 
about the way how they are treating patients with heart failure(5). Among other, reasons for 
not giving β-blockers, an important cornerstone in heart failure therapy, were asked. Many 
reasons were given, but most of them are no contra-indications following the current 
guidelines. Cardiologist did only slightly better than the other two groups. E.g. 60% of 
cardiologists and 70% of internists and geriatricians named COPD as a contra-indication 
although various studies have shown equal benefit from β-blocker treatment in these 
patients. Recently in the US, the impact of not following the guidelines was calculated 
theoretically. The authors concluded that as many as 68.000 lives could be saved each year 
in the US just by treating heart failure adequately(6)! 
Care processes in heart failure 
Why are not we doing any better than this? The complexity of treating patients with 
heart failure is a key issue. Many caregivers as well as the patients are involved in the 
treatment of heart failure. This not only includes the cardiologist and the general 
practitioner (GP), but depending on the individual need of a patient many other specialists, 
heart failure nurses, pharmacologist, dietist, physiotherapist and many other. Many 
questions in this complex network are not really addressed such as the most adequate 
caregiver at a certain time-point, most adequate ways of communication and 
documentation, adequacy of treatment and so forth. Many problems are to be addressed. 
They may include coordination of care, communication pathways, optimal way to approach 
multiple chronic disorders, benchmarking and adequacy of individual guidelines for different 
diseases, which may be contradictory in some aspects. Moreover, improvement of efficacy 
and efficiency to reduce costs at better quality has not been addressed. And very 
importantly, patients must be adequately integrated in the care process. Obviously, this long 
list is far from being complete. In addition, little is known about the importance of each of 
these hurdles. 
INTERACT-in-HF tries to answer many of these questions by investigating how the care-
process in heart failure is organized in order to define important bottlenecks. In this study, 
we are using a patient-centred, mixed-method research approach. Thus, we have 
interviewed 33 patients from our outpatient clinic to determine how care was carried out in 
each patient. Aspects of this include the diagnostic steps being made, the therapy given, 
caregivers involved, hurdles the patients experienced, etc. In addition, their cardiologists, 
heart failure nurses and GP’s were interviewed. Presently, we are interviewing 15 heart 
failure patients only seen in primary care and their GP’s to investigate important differences 
between primary and secondary care. Moreover, the approach is being applied in two 
regions in Germany and Belgium to address differences between different health care 
systems. The data are being verified by collecting data about the care process of another 150 
randomly selected heart failure patients from the patients’ records in each region.  
The experience of this study already helped to better define the needs for 
collaborating with GP’s in the region. The “1½ lijnzorg” project focuses in heart failure on 
best treatment in the whole care process, particularly the long-term treatment to implement 
“best practice” in the region. Obviously, the aim is also to define this more broadly and 
independently of the health care system to develop integrated care programs. An important 
basis for this will be the integration with ICT supported care. There is considerable 
experience with ICT supported care here in Maastricht(7, 8) and we are further developing 
and improving telemedicine in collaboration with an industrial partner. The aim is not only to 
provide easier access to care and improvement in the aspects mentioned above, but to also 
substitute care to some extent, resulting in reduction in cost and improvement in care 
likewise. Obviously, the ICT basis will additionally be used to implement results of the other 
initiatives as highlighted below as well as knowledge from basic research programs of 
CARIM. 
Best care known in all HF patients? Steps towards personalized medicine 
Guidelines give recommendations regarding all patients with heart failure. However, 
these recommendations are evidence based only in those aged 75 years or less with reduced 
left-ventricular ejection fraction (LVEF). In those with normal LVEF, so-called heart failure 
with preserved ejection fraction (HFpEF), no treatment is known to improve outcome(9). 
Only a limited amount of trials have been performed so far, of which all failed to show 
significant benefits. One important reason for this failure is the fact that HFpEF is, in our 
opinion, not one uniform disease with uniform pathophysiology. Therefore, we suggest a 
completely different approach to HFpEF by establishing a new outpatient clinic for these 
patients with an important focus on extensive diagnostics. This will help to much better 
address the underlying problems in individual patients which then can be targeted with 
specific therapies. We are establishing an electronic database and a biobank in these 
patients to further develop treatment algorithms for best practice in these patients. A very 
strong translational part is playing an important role in this, as the cohort will provide 
samples for basic research questions, will help to define new questions that can be address 
in basic research and will give the opportunity of bringing findings from basic research to 
these patients in urgent need for better therapy. 
Apart from this, the question arises to what extent personalized medicine is already 
implemented in the management of heart failure. The answer is to a very limited extent. 
Obviously, we are treating patients based on symptoms and we are treating underlying 
problems such as myocardial infarction or valvular diseases. We are treating complications 
of heart failure and we are adjusting medication based on tolerability. But, we would like to 
tailor therapy much more targeted to the individual need. This is to a large extent still 
fiction. Markers of prognosis might be helpful in this, but in clinical reality this is presently 
limited to the indication for cardiac transplantation. Some studies have used NT-proBNP to 
better guide therapy in heart failure patients, among those TIME-CHF in which I was 
substantially involved, is still the largest(10, 11). These studies suggested that NT-proBNP / 
BNP may be used to optimize therapy(12), but this is obviously a non-specific approach. 
Other biomarkers as well as genetic profiles are not yet studied to guide therapy. Therefore, 
we are using standard drug and device regimen according to the guidelines quite 
unselectively in treating our heart failure patients.  
There are, however, potential shortcomings in this. Thus, it is very likely that the 
premises are not the same for all patients and that effects of treatment are quite different 
between patients. As a consequence, the chance of a beneficial effect of a particular 
treatment is not really predicable. The questions as to whether there are better options than 
to give everything to everybody can probably be answered by saying yes, but this has not yet 
been studied. As suggested by studies such as TIME-CHF, biomarkers might play an 
important role in this regard. Biomarkers are markers of biological processes. Broadly 
spoken, this may include measures such as heart rate or blood pressure. Usually, the term 
biomarker refers, however, more specifically to markers circulating in the peripheral blood 
of which NT-proBNP used in TIME-CHF is a prominent example. There are currently many 
initiatives on biomarkers not just in heart failure, using 100s or even 1.000s of biomarkers. 
Given the complexity and the lack of understanding of many details on these biomarkers, I 
am convinced that these initiatives are likely to fail, at least in the short and mid-term. 
Therefore, we are using a different approach. In TIME-CHF, we measured 20 additional 
biomarkers at all visits when patients were seen during the study. Currently, we are 
investigating how the interaction between these biomarkers and the medication during the 
time-course of the study predicts the probability that patients are doing fine. In 
collaboration with the Department of Knowledge Engineering of Maastricht University and 
an industrial partner, we are looking for individual biomarkers that predict the effects of 
distinct classes of drugs on patient outcome. The figure depicts an example, showing a 
better response to high doses of β-blockers if the biomarker is low, but to low doses of β-
blockers if the biomarker is high. This would be a completely new concept in the treatment 
of heart failure that could result in a paradigm shift. If this new concept can be confirmed it 
would allow targeting specific treatment in individual patients. The results of TIME-CHF are 
currently tested in 4 other international cohorts of heart failure patients, including in total 
>5.000 patients. Both clinical data and blood samples to measure biomarkers are provided 
from these groups to us that we can further work out this concept. Initial results are very 
promising.  
 
Figure: from TIME-CHF(10) (left) to truly personalized heart failure medication. Middle figure 
shows example from interaction between biomarker and medication to predict treatment 
response. 
After validation of these results, prospective studies will be conducted. We are 
expecting to have the validation competed early next year. This would be a truly 
personalized approach for treatment of heart failure, beyond current practice. Based on 
individual patterns of clinical findings and biomarkers optimal therapy may be defined with 
high dose of drugs only where needed, but low doses or even omitting of some drugs where 
required. This will result in least side effects, best outcome and being most cost-efficacious. 
In a latter step, genetic information may be included. 
Co-Morbidities and patients’ wish 
In order to cover the “full picture”, consideration of the co-morbidities is additionally 
needed. It is known that each co-morbidity independently impact outcome in a negative 
way(13). Thus, the risk of more than one additional disease is additive, resulting in a huge 
increase in risk to die in such patients as compared to those only having heart failure. In 
addition to the increased risk, making optimal medical therapy becomes close to impossible 
as all these diseases require different treatment. Investigating heart failure in isolation, 
therefore, results in a major shortcoming for clinical practice. We are, therefore, 
investigating the interaction between heart failure and other diseases. One prominent 
example of this is the investigation of cognitive impairment in heart failure(14). Together 
with 3 other centres in the Netherlands, we are conducting comprehensive testing including 
imaging using MRI of heart, brain and cerebral vessels, cognitive assessment as well as 
biomarkers. Thus, the interaction between heart, blood flow to the brain and the brain is 
investigated in three populations: i.e. heart failure, carotid stenosis, and vascular cognitive 
impairment. Using such an integrative approach is also applied to other co-morbidities, 
particularly where needed most, which is in HFpEF patients. 
Finally, it is all about the patients. We tend to forget that patients may have other 
priorities than we think they have. Asking them about their preferences and their quality of 
life is therefore crucial. We did so and what we found was rather surprising to us. Thus, ¾ of 
the patients would not have been willing to give one single day of their remaining lifespan 
for a better quality of life; despite being elderly and having significant symptoms related to 
heart failure(15). This is a finding that is completely different to what we expected. And, it 
was not possible to predict the preferences of individual patients. This goes along nicely with 
the investigation of the care processes. Asking what it is all about is crucial; knowing is 
everything, guessing is nothing. Unfortunately, guessing is what we are often doing in the 
care of heart failure, but also when planning research. Our projects can be seen as a serious 
try to overcome this shortcoming. 
Conclusions and outlook 
The overall aims of the clinical heart failure group is, therefore, working towards 
personalized medicine in heart failure using a holistic approach. This does not only include 
heart failure itself, but also co-morbidities and patients’ preferences. It aims to setting up 
personalized therapy applied to the individual needs of heart failure patients covering the 
full spectrum. Moreover, it aims to much better facilitate heart failure care by knowing the 
important processes, identifying and targeting bottlenecks, and creating a basis that is 
widely applicable. ICT supported care will play an important role in this because 
comprehensive information over patients and their individual needs are crucial in this. 
Further development in collaboration with other academic and industrial partners is key and 
will include applications for EU grants. I am convinced that only a broad approach in clinical 
heart failure care as well as research will help to overcome current obstacles. 
Very important in this is the close collaboration with basic research because both sides 
are limited if there is no exchange. At first sight and as addressed here, there is much to be 
done to even implement current knowledge in clinical practice. Only focusing on this would, 
however, mean stagnation not only on longer term. Basic research is dependent on knowing 
the clinically important questions and needs a partner to bring their findings to patients, 
whereas clinical research is dependent on innovation and understanding of mechanisms, just 
to name a few important aspects of such interaction. There is, however, still a gap between 
the understanding of basic mechanisms and clinical practice. This gap is significantly 
hindering progress. Within the heart failure cluster, we are moving ahead with reducing this 
gap. Still, there are also threats. Given the constraints to reduce costs in health care, the 
mistake is often being made to prioritize research and education much lower than clinical 
care. As clinical research can somewhat more easily be integrated in clinical care and 
industrial money is more easily available for clinical research, it is mainly basic research that 
is suffering from this. On short term, this saves money. On the longer term, this questions 
the justification of existence of a university. There are other ways to reduce costs and to be 
more efficient. Thus, effort can be placed on optimizing processes and workflows. This has 
recently been started in our institution, but more needs to be done. Another example is the 
fact that the hospital and the university are still two different legal bodies; something I just 
do not understand and I have not heard any convincing reasons why this has not been 
changed. Maastricht - the university with all the schools and the hospital - is aiming high, but 
has to be aware what the consequences are to live up with this. The new developing 
cardiovascular centre with the very ambitious aims fits excellently in this. To be part of these 
new developments is very exciting and an important reason for me to work here. Thoroughly 
believing in it by all involved and putting the ambitions into practice even more than 
presently being done are crucial to reach these aims. I am proud to be part of it and to be 
able to contribute to the success of it. 
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